QOL-25. IMPACTS OF IMPLEMENTING A PROSPECTIVE TREATMENT AND SURVEILLANCE PROTOCOL FOR THE MANAGEMENT OF NF2-ASSOCIATED VESTIBULAR SCHWANNOMAS ON TUMOR GROWTH, HEARING OUTCOMES, AND QUALITY OF LIFE

Abstract Neurofibromatosis type 2 (NF2) is an autosomal dominant neurocutaneous syndrome associated with the development of nervous system tumors, including vestibular schwannomas (VS), meningiomas, and ependymomas. Although considered a rare illness, it source significant morbidity, mainly due to early hearing loss leading decreased autonomy productivity among young adults. Bevacizumab, monoclonal antibody against VEGF, has been shown improve audition tumor size in observational studies on NF2-associated VS. The most common limitations literature include lack reliable control groups, paucity data quality life, detailed audiology testing guidelines. Moreover, cost bevacizumab limiting factor access care. In our Canadian tertiary care center, offered NF2 patients VS complications without specific indications optimal treatment initiation time or duration. We present hybrid cohort study protocol retrospective prospective arms aimed at measuring impacts introducing standardized surveillance growth, outcomes, life. Patients from multidisciplinary neurofibromatosis clinic University Montreal Health Center, Canada, will be evaluated for inclusion arm through regular audiological evaluations imaging. Eligible individuals receive initial dose 5 mg/kg every weeks year while participating serial audiological, radiological, life assessments. results compared those historical cohort. Our primary outcomes growth rate (% per year) schwannomas, meningiomas ependymomas, test results, subjective estimated questionnaires (SF-36, SSQ). hypothesize that enrolled show improved clinical response